1. Epstein B. A Cellarful of Noise. Pocket Books, New York, 1967, 1998.
1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7:270–79.
2. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int J Geriatr Psychiatry. 2011; Jul 21. doi: 10.1002/gps.2758. [Epub ahead of print]
3. Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: Systematic review of the literature. Am J Geriatr Psychiatry. 2010;18:281–96.
4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7:263–69.
5. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–56.
6. Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol. 2002;59:594–600.
7. Buchman AS, Leurgans SE, Nag S, Bennett DA, Schneider JA. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke. 2011;42:3183–89.
1. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci. 1998;158:47–52.
2. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: A cause for concern in the elderly? Curr Opin Clin Nutr Metab Care. 2009;12:22–29.
3. Salustri C, Barbati G, Ghidoni R, et al. Is cognitive function linked to serum free copper levels?: A cohort study in a normal population. Clin Neurophysiol. 2010;121:502–7.
4. Lam PK, Kritz-Silverstein D, Barrett-Connor E, et al. Plasma trace elements and cognitive function in older men and women: The Rancho Bernardo study. J Nutrition. 2008;12:22–27.
5. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol. 2006a;63:1085–88.
6. Brewer GJ. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer’s disease. J Am Coll Nutr. 2009;28:238–42.
7. Schiepers OJ, van Boxtel MP, de Groot RH, et al. Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: Results from the FACIT study. J Gerontol A Biol Sci Med Sci. 2010;65:1312–21.
8. Shah RC, Wilson RS, Tang Y, Dong X, Murray A, Bennett DA. Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology. 2009;32:40–46.
9. Shah RC, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Hemoglobin level in older persons and incident Alzheimer disease: Prospective cohort analysis. Neurology. 2011;77:219–26.
10. Huang X, Cuajungco MP, Atwood CS, Moir RD, Tanzi RE, Bush AI. Alzheimer’s disease, beta-amyloid protein and zinc. J Nutr. 2000;130:1488S–92S.
11. Watt NT, Whitehouse IJ, Hooper NM. The role of zinc in Alzheimer’s disease. Int J Alzheimers Dis. 2011;971021.
12. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation in Alzheimer’s disease is a source of redox-generated free radicals. Proc Nat Acad Sciences of the United States of America. 1997;94:9866–68.
13. Environmental Protection Agency. Basic information about copper in drinking water. Internet: http://water.epa.gov/drink/contaminants/basicinformation/copper.cfm, accessed October 3, 2011.
14. Hunt JR. Bioavailability of iron, zinc, and other trace minerals from vegetarian diets. Am J Clin Nutr. 2003;78(suppl):633S–39S.
15. Hunt JR, Vanderpool RA. Apparent copper absorption from a vegetarian diet. Am J Clin Nutr. 2001;74:803–7.
16. Kadrabová J. Madaric A, Kováciková Z, Ginter E. Selenium status, plasma zinc, copper, and magnesium in vegetarians. Biol Trace Elem Res. 1995;50:13–24.
17. Crapper DR, Kishnan SS, Dalton AJ. Brain aluminum distribution in Alzheimer’s disease and experimental neurofibrillary degeneration. Science. 1973;180:511–13.
18. Crapper DR, Krishnan SS, Quittkat S. Aluminium, neurofibrillary degeneration and Alzheimer’s disease. Brain. 1976;99:67–80.
19. Miu AC, Benga O. Aluminum and Alzheimer’s disease: A new look. J Alzheimer’s Dis. 2006;10:179–201.
20. Bolognin S, Messori L, Drago D, Gabbiani C, Cendron L, Zatta P. Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity. Int J Biochem Cell Biol. 2011;43:877–85.
21. Martyn CN, Osmond C, Edwardson JA, Barker DJP, Harris EC, Lacey RF. Geographical relation between Alzheimer’s disease and aluminium in drinking water. Lancet. 1989;333:61–62.
22. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues J-F. Aluminum and silica in drinking water and the risk of Alzheimer’s disease or cognitive decline: Findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169:489–96.
23. Frecker MF. Dementia in Newfoundland: Identification of a geographical isolate? J Epidemiol Community Health. 1991;45:307–11.
24. Gauthier E, Fortier I, Courchesne F, Pepin P, Mortimer J, Gauvreau D. Aluminum forms in drinking water and risk of Alzheimer’s disease. Environ Res. 2000;84:234–46.
25. Forster DP, Newens AJ, Kay DW, Edwardson JA. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: A case-control study in northern England. J Epidemiol Community Health. 1995;49:253–58.
26. Taylor GA, Newens AJ, Edwardson JA, Kay DWK, Forster DP. Alzheimer’s disease and the relationship between silicon and aluminum in water supplies in northern England. J Epidemiol Community Health. 1995;49:323–28.
27. Forbes WF, McLachlan DR. Further thoughts on the aluminum-Alzheimer’s disease link. J Epidemiol Community Health. 1996;50:401–3.
28. Doll R. Review: Alzheimer’s disease and environmental aluminum. Age Ageing. 1993;22:138–53.
29. Alzheimer’s Association. Alzheimer’s Myths. Internet: http://www.alz.org/alzheimers_disease_myths_about_alzheimers.asp, accessed September 16, 2011.
30. Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer’s disease: The integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimer’s Dis. 2011;276393.
31. Duggan JM, Dickeson JE, Tynan PF, Houghton A, Flynn JE. Aluminum beverage cans as a dietary source of aluminium. Med J Aust. 1992;156:604–5.
32. Saiyed SM, Yokel RA. Aluminium content of some foods and food products in the USA, with aluminium food additives. Food Addit Contam. 2005;22:234–44.
33. Mutter J, Naumann J, Schneider R, Walach H. Mercury and Alzheimer’s disease. Fortschr Neurol Psychiatr. 2007;75:528–38.
34. Bates MN. Mercury amalgam dental fillings: An epidemiologic assessment. Int J Hyg Environ Health. 2006;209:309–16.
35. Saxe SR, Wekstein MW, Kryscio RJ, et al. Alzheimer’s disease, dental amalgam and mercury. J Am Dent Assoc. 1999;130:191–99.
1. Giem P, Beeson WL, Fraser GE. The incidence of dementia and intake of animal products: Preliminary findings from the Adventist Health Study. Neuroepidemiology 1993;12:28–36.
2. National Cancer Institute. Top food sources of saturated fat among US population, 2005–2006 NHANES. Internet: http://riskfactor.cancer.gov/diet/foodsources/sat_fat/sf.html, accessed October 2, 2011.
3. Morris MC, Evans EA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer’s disease. Arch Neurol. 2003;60:194–200.
4. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002;59:1258–63.
5. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627–37.
6. Laitinen MH, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: A population-based study. Dement Geriatr Cogn Disord. 2006;22:99–107.
7. Engelhart MJ, Geerlings MI, Ruitenberg A. Diet and risk of dementia: Does fat matter? The Rotterdam Study. Neurology. 2002;59:1915–21.
8. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28:75–80.
9. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: The cholesterol connection. Nature Neurosci. 2003;6:345–51.
10. Anoop S, Anoop M, Meena K, Luthra K. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. Indian J Med Res. 2010;132:363–78.
11. Petot GJ, Traore F, Debanne SM, Lerner AJ, Smyth KA, Friedland RP. Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism. 2003;52:279–81.
12. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;15:CD003160.
13. Heude B, Ducimetiere P, Berre C, EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study. Am J Clin Nutr. 2003;77:803–8.
14. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids. 2000;35:1305–12.
15. Kröger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of dementia: The Canadian Study of Health and Aging. Am J Clin Nutr. 2009;90:184–92.
16. Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: Current knowledge and practical implications. Am J Clin Nutr. 2003;78(suppl):640S–46S.
17. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: A randomized, double-blind, controlled trial. Am J Clin Nutr. 2010;91:1725–32.
18. Van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology. 2008;71:430–38.
19. Quinn JF, Rama R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA. 2010;304:1903–11.
20. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol. 2005;62:1849–53.
21. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr. 2011;93:601–7.
22. Tonstad S, Butler T, Yan R, Fraser GE. Type of vegetarian diet, body weight and prevalence of type 2 diabetes. Diabetes Care. 2009;32:791–96.
23. Marckmann P, Grønbaek M. Fish consumption and coronary heart disease mortality: A systematic review of prospective cohort studies. Eur J Clin Nutr. 1999;53:585–90.
24. Féart C, Samieri C, Rondeau V, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302:638–48.
25. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005;118:991–97.
26. Berkow S, Barnard ND. Vegetarian diets and weight status. Nutr Rev. 2006;64:175–88.
27. Turner-McGrievy GM, Barnard ND, Scialli AR. A two-year randomized weight loss trial comparing a vegan diet to a more moderate low-fat diet. Obesity. 2007;15:2276–81.
28. Gustafson D. An 18-year follow-up of overweight and risk of Alzheimer’s disease. Arch Intern Med. 2003;163:1524–28.
29. Berkow S, Barnard ND. Blood pressure regulation and vegetarian diets. Nutr Rev. 2005;63:1–8.
1. Devore EE, Grodstein F, van Rooij FJ, Hofman A, Stampfer MJ, Witteman JC, Breteler MM. Dietary antioxidants and long-term risk of dementia. Arch Neurol. 2010;67:819–25.
2. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287:3230–37.
3. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and cognitive change. Am J Clin Nutr. 2005;81:508–14.
4. Laurin D, Foley DJ, Masaki KH, White LR, Launer LJ. Vitamin E and C supplements and risk of dementia. JAMA. 2002;288:2266–68.
5. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–22.
6. Thomas RG, Gebhardt SE. Nuts and seeds as sources of alpha and gamma tocopherols. USDA-ARS Nutrient Data Laboratory, Beltsville, MD. Internet: http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Articles/AICR06_NutSeed.pdf, accessed June 17, 2011.
7. Brewer GJ. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer’s disease. J Am Coll Nutr. 2009;28:238–42.
8. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet. 2007a;369:208–16.
9. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int J Geriatr Psychiatry. 2011; Jul 21. doi: 10.1002/gps.2758. [Epub ahead of print]
10. Durga J, Verhoef P, Anteunis LJ, Schouten E, Kok FJ. Effects of folic acid supplementation on hearing in older adults: A randomized, controlled trial. Ann Intern Med. 2007b;146:1–9.
11. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636–43.
12. Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A 3rd. High homocysteine and low B vitamins predict cognitive decline in aging men: The Veterans Affairs Normative Aging Study. Am J Clin Nutr. 2005;82:627–35.
13. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer’s disease: A randomized controlled trial. JAMA. 2008;300:1774–83.
14. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag. 2010;6:775–85.
15. Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer’s disease. J Alzheimer’s Dis. 2006a;9:435–43.
16. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–88.
17. Feng L, Li J, Yap KB, Kua EH, Ng TP. Vitamin B-12, apolipoprotein E genotype, and cognitive performance in community-living older adults: Evidence of a gene-micronutrient interaction. Am J Clin Nutr. 2009;89:1263–68.
18. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006b;67:1370–76.
19. Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consumption and risk of stroke: A meta-analysis of cohort studies. Neurology. 2005;65:1193–97.
20. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: Meta-analysis of cohort studies. Lancet. 2006;367:320–26.
21. Oude Griep LM, Monique Verschuren WM, Kromhout D, Ocké MC, Geleijnse JM. Colours of fruit and vegetables and 10-year incidence of CHD. Br J Nutr. 2011a;106:1562–69.
22. Oude Griep LM, Vershuren WMM, Kromhout D, Ocke MC, Geleijnse JM. Colors of fruit and vegetables and 10-year incidence of stroke. Stroke. 2011b;42:3190–95.
23. Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr. 2010;103:730–34.
24. Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010;58:3996–4000.
25. Letenneur L. Risk of dementia and alcohol and wine consumption: A review of recent results. Biol Res. 2004;37:189–93.
26. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology. 2004;126:1293–1301.
27. Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer’s disease. J Alzheimer’s Dis. 2010;20:S167–74.
1. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353–64.
2. Yaffee K, Weston A, Graff-Radford NR. Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305:261–66.
3. Wilson RS, Bennett DA, Bienias JL, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology. 2002; 59:1910–14.
4. Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006; 296:2805–14.
5. Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: Systematic review of the literature. Am J Geriatr Psychiatry. 2010;18:281–96.
6. Craik FIM, Bialystok E, Freedman M. Delaying the onset of Alzheimer disease: Bilingualism as a form of cognitive reserve. Neurology. 2010; 75:1726–29.
7. Chertkow H, Whitehead V, Phillips N, Wolfwon C, Atherton J, Bergman H. Multilingualism (but not always bilingualism) delays the onset of Alzheimer disease: Evidence from a bilingual community. Alzheimer Dis Assoc Discord. 2010;24:118–25.
8. Kavé G, Eyal N, Shorek A, Cohen-Mansfield J. Multilingualism and cognitive state in the oldest old. Psychol Aging. 2008;23;70–78.
9. Inoue S, Matsuzawa T. Working memory of numerals in chimpanzees. Curr Biol. 2007;17(23):R1004–5.
10. Inoue S, Matsuzawa T. Acquisition and memory of sequence order in young and adult chimpanzees (Pan troglodytes). Anim Cogn. 2009;12,Suppl 1:S59–69.
1. Pereira AC, Huddleston DE, Brickman AM, et al. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA. 2007;104:5638–43.
2. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. J. Gerontol A Biol Sci Med Sci. 2006;61:1166–70.
3. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108:3017–22.
4. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;17:144:73–81.
5. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627–37.
6. Rovio S, Kareholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurology. 2005;4:705–11.
7. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. Psychol Med. 2009;39:3–11.
8. Foster PP, Rosenblatt KP, Kuljis RO. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer’s disease. Frontiers in Neurology. 2011;2:1–15.
9. Voss MW, Chaddock L, Kim JS, et al. Aerobic fitness is associated with greater efficiency of the network underlying cognitive control in preadolescent children. Neuroscience. 2011;29;199:166–76.
10. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27.
11. Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: A systematic review. Int J Obes (Lond) 2005;29:1168–74.
12. Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA. 2004;101:3316–21.
1. Wagner U, Born J. Memory consolidation during sleep: Interactive effects of sleep stages and HPA regulation. Stress. 2008;11:28–41.
2. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on aß dynamics in the human central nervous system. Arch Neurol. 2012;69:51–58.
1. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA. 2011;305:2556–64.
2. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy. 2009;29:800–811.
3. Cherrier M, Amory J, Ersek M, Risler L, Shen D. Comparative cognitive and subjective side effects of immediate release oxycodone in healthy middle age and older adults. J Pain. 2009;10:1038–50.
4. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005;294:183–93.
5. Le Pira F, Zappalà G, Giuffrida S, et al. Memory disturbances in migraine with and without aura: A strategy problem? Cephalalgia. 2000;20:475–78.
6. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: Results of an open-label study. Headache. 2001;41:377–84.
7. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.
8. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22.
9. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology. 2011;77:1126–34.
1. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease?: The Lifestyle Heart Trial. Lancet. 1990;336:129–33.
2. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001–7.
3. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005;118:991–97.
4. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat, vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006;29:1777–83.
5. Tonstad S, Butler T, Yan R, Fraser GE. Type of vegetarian diet, body weight and prevalence of type 2 diabetes. Diabetes Care. 2009;32:791–96.
6. Anderson JW, Gustafson NJ, Spencer DB, Tietyen J, Bryant CA. Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans. Am J Clin Nutr. 1990;51:1013–19.
7. Messina M, Messina V. The Simple Soybean and Your Health. Avery Publishing Group, Garden City Park, New York, 1994.
8. Mukuddem-Petersen J, Oosthuizen W, Jerling JC. A systematic review of the effects of nuts on blood lipid profiles in humans. J Nutr. 2005;135:2082–89.
9. Jenkins DJ, Kendall CW, Marchie A, et al. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr. 2005;81:380–87.
10. Davis BC, Kris-Etherton P. Achieving optimal essential fatty acid status in vegetarians: Current knowledge and practical implications. Am J Clin Nutr. 2003;78(suppl):640S–46S.
1. David Sheff. Interview with John Lennon and Yoko Ono. Playboy, January 1981. Internet: http://www.beatlesinterviews.org/db1980.jlpb.beatles.html, accessed September 3, 2011.
2. Ray Coleman. The Man Who Made the Beatles: An Intimate Biography of Brian Epstein. McGraw Hill, New York, 1989, pp. 10–15, 318–41.
3. Yeomans MR, Wright P, Macleod HA, Critchley JAJH. Effects of nalmefene on feeding in humans. Psychopharmacology. 1990;100:426–32.
4. Barnard ND, Noble EP, Ritchie T, et al. D2 Dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition. 2009;25:58–65.
5. The Vegetarian. February 1992. Internet: http://www.eatveg.com/paul.htm, accessed November 6, 2011.
1. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991–98.
2. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69:29–38.
3. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat, vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006;29:1777–83.
4. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: A randomized, controlled, 74-week clinical trial. Am J Clin Nutr. 2009;89(suppl):1588S–96S.
5. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005;118:991–97.
6. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med. 2003;9:448–52.
7. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. Published online, October 10, 2011.
8. Badiola N, Suárez-Calvet M, Lleó A. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. CNS & Neurological Disorders—Drug Targets. 2010;9:727–40.
9. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003;36:297–303.
10. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA. 2008;300:2253–62.
11. Snitz BE, O’Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA. 2009;302:2663–70.
12. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;21:CD003120.
13. Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr. 2010;47:246–55.
14. Richter Y, Herzog Y, Cohen T, Steinhart Y. The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: A pilot study. Clin Interv Aging. 2010;5:313–16.
15. Jorissen BL, Brouns F, Van Boxtel MP, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutritional Neuroscience. 2001;4:121–34.